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Abstract
We developed a novel injectable carrageenan/fibrin/hyaluronic acid-based hydrogel with in situ
gelling properties to be seeded with chondrogenic cells and used for cartilage tissue engineering
applications. We first analysed the distribution within the hydrogel construct and the phenotype of
human articular chondrocytes (HACs) cultured for 3 weeks in vitro. We observed a statistically
significant increase in the cell number during the first 2 weeks and maintenance of cell
viability throughout the cell culture, together with the deposition/formation of a cartilage-specific
extracellular matrix (ECM). Taking advantage of a new in vivo model that allows the integration
between newly formed and preexisting cartilage in immunodeficient mice to be investigated, we
showed that injectable hydrogel seeded with human articular chondrocytes was able to regenerate
and repair an experimentally made lesion in bovine articular cartilage, thus demonstrating the
potential of this novel cell delivery system for cartilage tissue engineering. Copyright  2009 John
Wiley & Sons, Ltd.
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1. Introduction
Tissue loss, as a result of trauma, congenital disorders
and joint diseases, usually involving structural damage of
articular cartilage surface, is a relevant clinical problem
(Cancedda et al., 2003; Tuli et al., 2003). In fact these
pathologies result in severe pain and disability for millions
of people worldwide and represent a major challenge for
orthopaedic surgeons (Hunziker, 1999, 2000; Temenoff
and Mikos, 2000b; Giannoni and Cancedda, 2006).
Tissue engineering (TE) can be defined as the art
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of reconstructing tissues (Cancedda et al., 2003), both
structurally and functionally, with the knowledge that
reconstruction can be performed either entirely or
partially in vitro and then completed in vivo (Temenoff
and Mikos, 2000b; McHale et al., 2005; Ando et al., 2007;
Endres et al., 2007; Eyrich et al., 2007a, 2007b).
During the past decade exciting new tissue-engineering
strategies have emerged that show the potential to regen-
erate damaged cartilage (Hunziker, 2000; Temenoff and
Mikos, 2000b; Gelse and Schneider, 2006). In particular,
autologous chondrocyte transplantation (ACT), a stan-
dard clinical procedure to treat human articular cartilage
defects (Brittberg et al., 1994; Peterson et al., 2000), has
been successfully used on thousands of patients. How-
ever, ACT, in addition to some intrinsic limitations, such
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as a poor in vitro expansion of chondrocytes and some
complexity in the graft fixation, requires an invasive sur-
gical technique. To overcome some of these problems,
new materials and new models have been studied and
proposed as cell delivery systems (Temenoff and Mikos,
2000b; Lee and Mooney, 2001; Chung and Burdick,
2008).
A very new and exciting approach to cell delivery for
tissue engineering is using hydrogels, which have the
ability to be injected into the body as a solution and
to form a gel immediately after injection, thus enabling
the clinician to transplant the cell-support system in a
minimally invasive manner. The use of materials that
present an injectable formulation satisfies also the need
of a perfect filling of the lesion, as they can also be easily
applied in the presence of an irregular defect (Gutowska
et al., 2001; Lee and Mooney, 2001; Park et al., 2007).
Biodegradable and biocompatible hydrogels with
components and structure similar to the extracellular
matrices (ECM) present in different districts of the body
have found numerous applications in the fields of TE
and in drug delivery (Temenoff and Mikos 2000a; Park
et al., 2005; DeFail et al., 2006; Endres et al., 2007;
Eyrich et al., 2007b; Park et al., 2007). In particular,
several scaffolds/hydrogels have been proposed in
association with different cell types for articular cartilage
regeneration (Temenoff and Mikos, 2000a; Gutowska
et al., 2001; Cancedda et al., 2003; Neuss et al., 2008).
Although the use of synthetic hydrogels appears very
promising, there are some important aspects that must be
investigated before they can be widely used in clinical
practice (Cancedda et al., 2003; Chung and Burdick,
2008). More specifically, the interactions of the cells
with the hydrogels can interfere with cell adhesion,
as well as with cell proliferation and migration, the
adhesion being cell-type specific and dependent on the
interactions of specific cell receptors with components
adsorbed or encapsulated into the materials (e.g. ECM
macromolecules and growth factors).
The aim of this study was to investigate some of these
aspects in the case of a new biodegradable carrageenan-
based injectable gel. Recent papers described a new organ
culture model in which human articular chondrocytes
were cultured within an experimentally made osteochon-
dral defect in an articular cartilage biopsy subcutaneously
implanted in an immunodeficient mouse (Mueller-Rath
et al., 2007; Schuller et al., 2008). We adopted a simi-
lar approach to show that carrageenan-based hydrogel,
seeded with human articular chondrocytes (HACs), has
the potential to regenerate and repair an articular defect.
2. Materials and methods
2.1. Hydrogel preparation
κ- and ι-carrageenans (Sigma-Aldrich, Germany) were
dissolved in double-distilled water (0.8% and 1.2%
w/v, respectively) and the solution was heated at 65 ◦C
under constant stirring to obtain a final homogeneous
preparation. Carrageenans are high molecular weight
sulphated polygalactans derived from several species of
red seaweeds (Rhodophyceae). The most common forms
of carrageenan are lambda (λ), kappa (κ) and iota (ι).
Carrageenan has alternating disaccharide units composed
of D-galactose-2-sulphate and D-galactose-2,6-disulphate,
the galactose residues being joined by -1,3 and -1,4
linkages. These polysaccharides form gels upon cooling in
the presence of specific ions, due to the development of
3D networks as the result of the formation of helical chain
complexes. In the presence of K+ ions, κ-carrageenan
forms strong crisp gels, whereas ι-carrageenan in the
presence of Ca2+ ions forms elastic gels (Bartkowiak and
Hunkeler, 2001; Thommes and Kleinebudde, 2008).
Fibrinogen (final concentration, 3000 KalliKrein-
inhibitor-units (KIU/ml); Baxter AG, Austria) and throm-
bin (final concentration, 500 U/ml; Baxter) were dis-
solved in an aprotinin solution (10 000 KalliKrein-
inhibitor-units (KIU/ml; Baxter) and in 40 mM CaCl2,
respectively. Human chondrocytes, harvested from a
human knee biopsy (Figure 1A, B) and cultured in serum-
free medium (see following paragraph) were resuspended
at a concentration of 2× 106 cells/ml in culture medium
(Biochrom AG, Berlin, Germany) containing 0.265 g/l
CaCl2 and 0.4 g/l KCl in order to trigger gel formation
when mixed with the carrageenan polymeric solution.
The cell suspension was supplemented with the thrombin
solution (5.9% v/v) and with 0.75% v/v hyaluronic acid
before being loaded into syringe a of the injection system
(Figure 1C). Syringe b was loaded with the carrageenan
solution supplemented with the fibrinogen solution at
35% v/v. The carrageenan/fibrinogen solution was mixed
with the cells/thrombin/hyaluronic acid solution by acti-
vating the two syringes at the same time. The gel formed
almost instantaneously.
2.2. In vitro cell culture
Articular cartilage biopsies were collected from male or
female patients (aged 61–75 years) undergoing total knee
arthroplasty. Patients had signed an informed consent
document approved by the Ethical Committee of the San
Antonio Hospital, Recco, Italy.
Briefly, cartilage was cleaned of connective tissue
and/or subchondral bone and cut into small fragments,
according to published procedures (Malpeli et al., 2004).
Individual HACs were released by repeated enzymatic
digestions with collagenase I (400 U/ml), collagenase
II (1000 U/ml; Worthing Biochemical, Lakewood, NJ,
USA), hyaluronidase (1 mg/ml; Sigma, St. Louis, MO,
USA) and 0.25% trypsin (Invitrogen Life Technologies,
Carlsbad, CA, USA) at 37 ◦C. Cells were pooled, counted
and seeded in culture dishes precoated for 24 h with
10% fetal calf serum (FCS) in culture medium (Biochrom
A.G. Berlin, Germany) to allow attachment of the
serum fibronectin to the plastic dish surface. After
48 h from seeding, the chondrocytes were enzymatically
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Figure 1. Scheme of the procedure followed to form the hydrogel. (A) Human articular chondrocytes biopsy and digestions.
(B) Light microscopy of a primary monolayer culture in serum-free (SF) medium before the recovery of the in vitro expanded cells.
(C) Biodegradable hydrogel system: content composition in syringes a and b and gross morphology of the formed gel
detached, collected, washed in PBS, counted and re-
plated in dishes pre-rinsed several times with PBS
to remove any residual trace of serum. The culture
medium was then replaced with the serum-free (SF)
medium described by Malpeli et al. (2004) and the cells
expanded in vitro in this culture condition. The medium
was changed three times/week. After four to five cell
doublings, HACs were collected and either encapsulated
within the tissue engineering construct and the culture
continued in chondrogenic medium (Johnstone et al.,
1998) for 3 weeks, or pelleted by centrifugation (2.5×
105 cells) and cultured in chondrogenic medium for
3 weeks.
2.3. Cell imaging
Over the course of the culture, the engineered constructs
(n = 3) were monitored using a brightfield light micro-
scope (Axiovert 10, Zeiss, Germany) equipped with a
digital camera (Olympus DP 10, Olympus Optical, Japan).
Images were acquired at ×5 and ×10 magnifications.
To assess live cells distribution, the constructs were
incubated with the nuclear staining Hoescht 33 342
(Sigma-Aldrich, Germany) at a final concentration of
5 µg/ml in culture medium for 30 min.
Optical sections along the z axis were then acquired by
structured epifluorescent illumination, using an Axiovert
200M microscope equipped with the Apotome module,
filter set 49 and an AxiocamHR camera (Carl Zeiss,
Jena, Germany). Image acquisition stacking of the optical
sections and 3D reconstruction of the samples were
performed using Axiovision Software (Carl Zeiss) (Frey
et al., 2006; Osakada et al., 2008).
2.4. MTT analysis
The viability of encapsulated HAC within the hydrogel
was evaluated at different time intervals, using thiazolyl
blue staining (MTT, Sigma-Aldrich), in which absorbance
data correlate to cell number. Briefly, in triplicate sample
culture, at each time point the medium was removed
and replaced with 0.5 ml fresh serum-free medium
supplemented with 25 µl MTT stock solution (5 mg/ml).
After 3 h incubation, the medium was collected and
the converted dye was solubilized with 1 ml absolute
ethanol. Dye absorbance was measured at 570 nm with
background subtraction at 670 nm (Denizot and Lang,
1986).
2.5. Semi-quantitative reverse
transcriptase–polymerase chain reaction
(RT–PCR)
RNA was extracted using the TRIzol reagent (Invitrogen,
Carlsbad CA, USA) procedure (Ulivi et al., 2006).
Conditions for semi-quantitative RT–PCR are described in
Banfi et al. (2000). The mRNAs analysed were aggrecan,
α1 (I) collagen (collagen type I), α1 (II) collagen (collagen
type II) and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). Primer sequences were as follows:
Aggrecan: forward, 5′-ATGCCCAAGACTACCAGTGG – 3′,
reverse, 5′-GTGAGCTCCGCTTCTGTAGT-3′
Collagen type I: forward, 5′-TCTGCGACACAAGGAGTC-
TG – 3′, reverse, 5′-CGACCCACACTTCCATCACT-3′
Collagen type II: forward, 5′-TCTGCAACATGGAGACTA-
GC-3′, reverse, 5′-GAAGCAGACAGGCCCTATGT-3′
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GAPDH: forward, 5′-CCATCTTCCAGGAGCGAGAT-3′,
reverse, 5′-CTGCTTCACCACCTTCTTGAT-3′
Following a 4 min denaturation step at 95 ◦C, the
adopted reaction profiles were: aggrecan, collagen type
I and GAPDH, 95 ◦C for 1 min, 55 ◦C for 1 min and 72 ◦C
for 1 min for 25 cycles; collagen type II, 95 ◦C for 1 min,
60 ◦C for 1 min and 72 ◦C for 1 min for 30 cycles. All PCRs
ended with 8 min incubation at 72 ◦C. The values of the
cycles used were in the linear range of amplification, as
determined previously during preliminary experiments.
PCR products were run on 1% agarose gels and visualized
using ethidium bromide. Reaction product sizes were:
aggrecan, 448 bp; collagen type I, 599 bp; collagen type II,
517 bp and GAPDH, 450 bp.
2.6. Bovine organ culture defect model
Bovine articular cartilage was harvested from the knees
of 18 month-old cows, washed twice with PBS and cut
into regular cubes of about 1.5× 1.5× 0.5 cm. Cartilage
defects were created on the cartilage surface using a
drilling device (0.4 cm) under sterile conditions. The
defects were then filled with hydrogel seeded or not
seeded with 2× 106/ml cells. Six engineered cartilage
pieces were subsequently implanted subcutaneously in
immunodeficient mice (nu/nu) and the animals were
sacrificed after 4, 6 and 8 weeks to recover the cartilage
pieces. All animals were treated and handled according
to institutional guidelines.
2.7. Histology and immunohistochemistry
Histological samples were rinsed three times in PBS and
then fixed in 4% formaldehyde in PBS for 6 h. After
fixation, the samples were dehydrated by serial immersion
in ethanol solutions (70%, 90%, 95% and 100%) and
xylene. Specimens were then embedded in paraffin and
5 µm sections were cut using a microtome (Leica RM
2165). Sections were then dewaxed and stained with
toluidine blue (Merck, Darmstadt, Germany), or Alcian
blue (Sigma-Aldrich Chemical, St. Louis, MO, USA) to
reveal cartilage matrix components.
For immunohistochemical analysis, serial sections of
paraffin-embedded samples were dewaxed and treated
with methanol :H2O2 (49 : 1) for 30 min to inhibit
endogenous peroxidases. The sections were then treated
with 1 mg/ml hyaluronidase in PBS, pH 6.0, for 20 min
at 37 ◦C and washed with PBS. After incubation with
goat serum for 1 h to reduce non-specific binding, the
specific antibody was added and incubated for 1 h at room
temperature. Sections were washed several times in PBS
and challenged with biotinylated anti-mouse IgG (Jackson
Laboratory Inc., West Grove, PA, USA) and peroxidase-
conjugated egg-white avidin (Jackson Laboratory). After
additional washing of the sections with PBS and 50 mM
sodium acetate, pH 5.0, the peroxidase activity was
visualized by enzymatic modification of the 3-amino-
9-ethylcarbazole substratum (3-amino-9-ethylcarbazole
0.4% in dimethylformamide:50 mM sodium acetate, pH
5 : 30% H2O2; 100 : 900:1) performed in the dark at room
temperature for 15 min. Sections were counterstained
with Harri’s haematoxylin and mounted with Gel Mount
(Biomeda Corp., Foster City, CA, USA). The slides were
observed and images acquired with the Axiovert 200M
microscope (Carl Zeiss).
The specific antibodies were an anti-type II collagen
monoclonal antibody (CIICI anti-COLLII, DSHB, Univer-
sity of Iowa) and anti-human Tenascin monoclonal anti-
body (a generous gift from Dr E. Balza, Istituto Nazionale
per la Ricerca sul Cancro, Genova).
2.8. Statistical analysis
All data were analysed by one-way ANOVA, followed by
a post hoc comparison with Turkey’s HDS. Differences
were accepted to be statistically significant at p < 0.05.
All errors are given as standard deviations.
3. Results
3.1. In vitro culture of articular chondrocytes
seeded into the injectable hydrogel
Human articular chondrocytes were expanded up to
a maximum of five doublings in serum-free medium.
This culture condition also allows the proliferation of
chondrocytes derived from elderly donors, maintaining at
the same time the cell chondrogenic potential needed for
therapeutic application (Dozin et al., 2002).
Cells grown in monolayer were detached and resus-
pended at a concentration of about 4× 106/ml in a
solution containing hyaluronic acid and thrombin and
loaded into syringe a of a Duploject syringe support
(included in the Tissucol Kit, Baxter). Syringe b was
loaded with a solution containing fibrinogen and κ- and
ι-carrageenan. Upon mixing, the two solutions almost
instantaneously formed a gel containing the cells; for
each sample, the total volume of the gel was about
250 µl. Chondrocytes embedded in this gel were cultured
in 1.5 ml chondrogenic medium (Johnstone et al., 1998)
for 3 weeks.
Cell morphology and distribution within the gel were
examined by microscopy at several time points during
in vitro culture. Immediately after the hydrogel formation,
the cells appeared round and homogeneously distributed,
but during the first week of culture they showed a
tendency to form clusters (Figure 2A, B). After 3 weeks
we observed a transition of the encapsulated chondrocytes
from an aggregate status to a more homogeneous and
uniform distribution (Figure 2D, E). Optical sections
of the specimens incubated with Hoechst dye and
subsequent 3D reconstruction allowed the identification
and the visualization of the cells yielding, an accurate
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3D distribution of these within the scaffolds (Figure 3).
Distribution of human chondrocytes over the total depth
of the gel was observed after both 1 and 3 weeks of culture
(Figure 3).
Viability of encapsulated cells within the polysaccharide
biodegradable hydrogel during the 3 weeks of culture
was confirmed using MTT analysis. The number of
cells increased during the initial 2 weeks of culture
Figure 2. Light microscopy images of the hydrogel containing
the human chondrocytes after 1 week (A, B) and 3 weeks (D, E)
of culture. A control hydrogel not seeded with cells after 1 week
of culture is shown in (C). Bar = 50 µm
and remained viable over the remaining culture period
(Figure 4). These data demonstrated that human articular
chondrocytes, after their expansion as a monolayer
culture in serum-free medium, once seeded within
the biodegradable hydrogel, maintain a proliferation
potential and remain viable.
Figure 4. Viability of human chondrocytes during the culture
within the tissue-engineered construct as revealed by MTT
staining. Error bars represent mean ± SD. Statistical analysis
by ANOVA with significant differences accepted to be p < 0.05.
T0 vs. T3w (p < 0.05); HSD (0.05) = 0.9; HSD (0.01) = 1.23; MS
error = 0.1182; df error = 8; p = 0.034
Figure 3. Representative images of live human articular chondrocytes within the tissue-engineered constructs at 1 (A, C) and
3 weeks (B, D) of culture after labeling of the cell nuclei with Hoechst and optical sectioning by structured epifluorescent
illumination. Image projections along the x, y and z axes (A, B) and their respective 3D reconstructed stacks (C, D) are shown
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3.2. In vitro cartilage formation
To test the capability of the hydrogel embedded cells to
form cartilage, human articular chondrocytes expanded in
monolayer were seeded into the hydrogel and maintained
for 3 weeks in chondrogenic medium. At the end of
monolayer culture and before encapsulation into the
hydrogel (T0), human articular chondrocytes expanded
in the presence of serum-free medium expressed the
chondrocyte-specific aggrecan and type II collagen mRNAs
and, as expected, also type I collagen mRNA (Figure 5).
After 3 weeks of in vitro culture within the gel (TF), the
encapsulated human articular chondrocytes maintained
the expression of aggrecan and type II collagen but
stopped the expression of type I collagen.
As a further control, at the time of the establishment
of the culture within the hydrogel, an aliquot of the
cells from the monolayer culture was used to establish a
parallel in vitro micromass pellet culture (Malpeli et al.,
2004) that was maintained in the same chondrogenic
medium as the hydrogel culture. Histological analyses
were performed for both the hydrogel and the micromass
in vitro culture after 3 weeks.
Mucopolysaccharides and glycosaminoglycans, char-
acteristic of the cartilage ECM, revealed by toluidine
(Figure 6B, D) and Alcian blue (Figure 6A–C) were
detected in the micromass pellet, as described by John-
stone et al. (1998), and in hydrogel culture after 3 weeks.
It was noteworthy that the distribution of the cartilage
matrix in the hydrogels was more homogeneous than in
the micromass pellets, where it was preferentially located
at the peripheral regions.
Figure 5. Expression of chondrogenic marker genes by
3D-cultured articular chondrocytes. Reverse-transcribed cDNA
was amplified by PCR with specific primers for the housekeep-
ing gene GAPDH (5698 bp), collagen type I (750 bp); collagen
type II (517 bp) and aggrecan (448 bp). Ladder, DNA molecular
weight markers (in base pairs) is shown on the left side; T0,
expanded chondrocytes before encapsulation; TF, encapsulated
chondrocytes after 3 weeks of in vitro culture
3.3. In vivo implantation of human articular
chondrocytes-hydrogel constructs
The immunodeficient mouse model is a well-established
method to investigate in vivo engineering of cartilage
and bone (Hunziker, 1999; Liu and Cao, 2007; Mueller-
Rath et al., 2007). Nevertheless, in the case of cartilage
engineering, one of the major limitations of this method is
the lack of an appropriate articular cartilage surrounding
the newly formed tissue, and therefore the impossibility
of investigating the integration of the newly formed
cartilage with the pre-existing cartilage. We used an
organ culture model, recently described (Mueller-Rath
et al., 2007; Schuller et al., 2008), in which the hydrogel,
including encapsulated HACs, was directly injected into
the defect created on the surface of the bovine articular
cartilage layer (Figure 7). The cartilage biopsy with the
hydrogel was maintained in culture in chondrogenic
medium for 1 week, then implanted subcutaneously in
the immunodeficient mouse. Histological analysis was
performed on cross-sections of the recovered samples
after 4, 6 and 8 weeks of implantation (Figure 8).
Macroscopic inspection of the retrieved implanted
construct showed a smooth surface and a complete
integration of the HAC–hydrogel with the surrounding
cartilage (Figure 8).
Histological examination of the sample revealed the
repair of the bovine cartilage defect by a cartilage tissue.
The newly formed cartilage showed matrix deposition
and uniform cellularity, it was clearly stained by toluidine
blue (Figure 8A–C, E) and was positive for the presence
of type II collagen (Figure 8F). Moreover, at the tissue
interface a good integration and grip between the newly
formed human cartilage and the surrounding bovine
cartilage was observed. In a control biopsy treated with
the hydrogel without cells, we failed to detect a newly
formed organized cartilage and an integration of the
Figure 6. Histological cross-sections of the hydrogel (A, B) and
micromass pellet (C, D) after 3 weeks of culture. Sections were
stained with Alcian blue (A, C) and toluidine blue (B, D).
Bar = 50 µm
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Figure 7. Contained-defect organ culture model: bovine cartilage defects filled with hydrogel containing human articular
chondrocytes (A); organ construct model implanted for 6 weeks in an immunodeficient mouse (B)
tissue filling the gap with the bovine cartilage (Figure 8D).
The origin of the neoformed cartilage was confirmed by
immunolocalization of human tenascin, taking advantage
of a specific monoclonal antibody which stained the
human chondrocytes in the neoformed tissue and not
those in the surrounding bovine cartilage (Figure 9A, B).
4. Discussion
Cartilage tissue engineering is an emerging approach
for the regeneration of cartilage tissue damaged due
to disease or trauma. Since cartilage lacks spontaneous
regenerative capabilities, it is essential to develop
methodologies for the delivery of appropriate cells,
biomaterials and factors to the defect site. The articular
chondrocyte transplantation technique (Brittberg et al.,
1994; Peterson et al., 2000) is a commonly used
method for cartilage repair, requiring a first arthroscopic
intervention to harvest the healthy cartilage sample,
from which chondrocytes are isolated and expanded
in vitro. With a second arthrotomy intervention, these
cells are then delivered to the cartilage defect site under
a periosteal or synthetic membrane flap.
The goal of this study was to determine the possibility of
delivering human articular chondrocytes by encapsulating
them in a novel, easy-to-handle, biodegradable hydrogel,
with in situ gelation properties and not affecting cell
chondrogenic differentiation. We developed a suitable
injectable biomaterial obtained by the mixture of
hyaluronic acid, fibrinogen, thrombin and carrageenan.
Carrageenans are heteropolysaccharides structurally
related to agar (Bartkowiak and Hunkeler, 2001). They
are extracted from red algae and come in three types, κ ,
ι and λ, that can form upon cooling a variety of gels. The
rationale of using a carrageenan hydrogel, rather than gels
made of synthetic polymers or other polysaccharides, was
mainly based on the ability of these polysaccharides to
form a gel at conditions that allow the direct encapsulation
of mammalian cells. These polysaccharides are water-
soluble when heated and gel upon cooling the solution
in presence of electrolytes (Ca2+ and K+) (Eyrich et al.,
2007b). In the conditions described in our study, we were
able to mix the cell suspension with the polysaccharide
solution and then form a gel at temperatures in the
range 36–40 ◦C with retention of cell viability. κ- and
ι -carrageenan are commonly used to produce pellets,
tablets or beads for drug delivery (Bartkowiak and
Hunkeler, 2001; Piyakulawat et al., 2007; Thommes and
Kleinebudde, 2008).
Hyaluronic acid (HA) is a major constituent of the
cartilage extracellular matrix. Its biological properties and
rapid degradation makes HA an ideal candidate for the
development of new biomaterials (Liao et al., 2005; Kim
et al., 2007). Fibrinogen/fibrin was selected because of
its adhesive properties. Moreover, various studies have
reported the use of fibrin gel as an injectable scaffold
for generating new cartilage matrix (Eyrich et al., 2007a,
2007b).
We performed preliminary studies with gels composed
of only HA and fibrin. When the articular chondrocytes
or other types of cells were encapsulated in this gel,
within a few days we observed a drastic shrinkage of
the scaffold. Indeed, these unpublished observations are
in agreement with recently published data (Eyrich et al.,
2007a). Therefore, to improve the quality of the hydrogel,
we introduced carrageenan into the HA–fibrin gel. With
this new gel composition, we observed no shrinking
effects; on the contrary, the gel presented a good elasticity
as well as a better stiffness.
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Figure 8. Histological cross-sections of the hydrogel within the bovine cartilage gap after 6 weeks from the implantation in
immunodeficient mouse. Toluidine blue staining (A–E); immunohistochemical staining showing localization of type II collagen
(F); negative control without primary antibody (G); control sample not seeded with cells (D). BAC, bovine articular cartilage; HAC,
human articular cartilage. Bar = 50 µm. Arrows indicate the new human cartilage deposition and a good integration of the tissue
Chondrocytes suspended in a 3Dmatrix, similar to their
natural environment, retain their native phenotype and
organize a cartilage extracellular matrix. Hydrogel scaf-
folds appear to satisfy this requirement. We encapsulated
human articular chondrocytes into this novel polysac-
charide/fibrin hydrogel and cultured them in vitro for
3 weeks. Our data indicate that this injectable scaffold
sustains an initial cell growth without compromising the
cell chondrogenic potential.
The growth and the distribution of the cells within
the hydrogel were qualitatively confirmed via images
obtained by histology using brightfield and epifluorescent
light microscopy. In particular, structured epifluorescent
illumination and optical sectioning allowed the acquisi-
tion of images through most of the hydrogel thickness
without the need of any manipulation, such as the
dehydration required for histology that may introduce
artifacts. This analysis revealed a uniform distribution
of viable human articular chondrocytes throughout the
hydrogel up to 3 weeks of culture.
After an encapsulation period of 3 weeks into the
tissue-engineered construct, cells not only maintained the
expression of proteins characteristic of the chondrogenic
lineage but also downregulated the expression of type I
collagen characteristically expressed by dedifferentiated
articular chondrocytes and by articular chondrocytes
expanded in monolayer culture in serum-free medium.
We are aware that chondrocytes harvested from
osteoarthritic patients are not the best source of cells
for cartilage regeneration. Chondrocytes harvested from
healthy tissue or other cell populations, such as mesenchy-
mal stem cells, may have led to even better results.
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Figure 9. Histological cross-sections of the hydrogel within
the bovine cartilage gap after 6 weeks from implantation
in immunodeficient mouse. The neocartilage formed shows
strong staining with toluidine blue (A). The specific anti-human
tenascin antibody recognizes only chondrocytes in the newly
formed cartilage in the gap defect (B). BAC, bovine articular
cartilage; HAC, human articular cartilage. Bar = 50 µm. White
arrows show the area of integration of human articular cartilage
in the bovine tissue. Black arrows show the human chondrocyte
cells
To provide a definitive assessment concerning the
suitability of a new biomaterial for cartilage tissue engi-
neering, in vivo models are required. The ‘conventional’
immunodeficient mouse model can support cartilage for-
mation but fails in investigating integration of the newly
formed cartilage within a pre-existing cartilage. There-
fore, in our study we used a contained-defect organ
culture model, recently described by Mueller-Rath et al.
(2007) and Sculler et al. (2008). This experimental model
mimics a real clinical intra-articular situation where the
repair tissue is having direct contact with the surrounding
cartilage. In view of the difficulties in harvesting human
articular cartilage, we have been forced to used two dif-
ferent species to test the capability of human articular
chondrocytes expanded in vitro to regenerate tissue in a
bovine cartilage lesion.
Using this approach, we observed a good integration
between the human cartilaginous tissue formed in the
articular cartilage defect and the surrounding bovine
cartilage after 6 weeks from the implantation.
5. Conclusions
In this study, we demonstrated the suitability for
cartilage engineering of a newly developed injectable gel.
Within this novel hydrogel, encapsulated human articular
chondrocytes remained viable, proliferated, maintained
the expression of the typical chondrogenic marker genes
and deposited a cartilage ECM. Taking advantage of
a new in vivo model, we showed the integration of
the newly formed cartilage with the surrounding pre-
existing cartilage. We propose that the novel hydrogel we
developed may be used with success to deliver ex vivo
expanded articular chondrocytes by arthroscopy injection
to the site of the articular cartilage lesion, and therefore
to repair the articular cartilage damage using a minimally
invasive technique.
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